What is claimed is:

1. A carrier composition for transdermal delivery of a macromolecule, comprising a phosphatidylcholine component entrapping said macromolecule, wherein said component stabilizes said macromolecule at room temperature.

2. The composition of claim 1, wherein said phosphatidylcholine component comprises phosphatidylcholine and at least one polyglycol.

3. The composition of claim 2, wherein said phosphatidylcholine is polyenylphosphatidylcholine-enriched phosphatidylcholine.

4. The composition of claim 2, wherein said polyglycol is polyglycol E200 and polyglycol E400.

5. The composition of claim 2, wherein said phosphatidylcholine component comprises 45% w/w phosphatidylcholine, 50% w/w polyglycol E200, and 5% w/w polyglycol E400.

6. The composition of claim 2, further comprising a surfactant, a lubricant, and methyl paraben.

7. The composition of claim 6, comprising 97.25% w/w phosphatidylcholine component, 1.00% w/w surfactant, 1.00% w/w lubricant, and 0.75% w/w methyl paraben.

8. The composition of claim 6, wherein said carrier further comprises water.

9. The composition of claim 8, wherein said carrier comprises 53.25% w/w phosphatidylcholine component, 1.00% w/w surfactant, 1.00% w/w lubricant, 0.75% w/w methyl paraben and 45% w/w water.

10. The composition of claim 6, wherein said surfactant is a siloxylated polyether.

11. The composition of claim 10, wherein said siloxylated polyether is dimethyl, methyl(propylpolyethylene oxide propylene oxide, acetate) siloxane.

12. The composition of claim 6, wherein said lubricant is silicone fluid.

13. The composition of claim 12, wherein said silicone fluid contains low viscosity polydimethylsiloxane polymers.

14. The composition of claim 1, wherein said macromolecule is selected from the group consisting of oxytocin, vasopressin, insulin, somatotropin, calcitonin, chorionic gonadotropin, menotropins, follitropins, somatostatins, progestins, peptides, polymers, and combinations of any of these.

15. A stable topical insulin composition, comprising:
carrier having a phosphatidylcholine component, and
insulin entrapped within said carrier.

16. The composition of claim 15, wherein said phosphatidylcholine component comprises polyenylphosphatidylcholine and at least one polyglycol.

17. The composition of claim 16, wherein said polyglycol is polyglycol E200 and polyglycol E400.

18. The composition of claim 17, wherein said phosphatidylcholine component comprises 45% w/w polyenylphosphatidylcholine, 50% w/w polyglycol E200, and 5% w/w polyglycol E400.

19. The composition of claim 15, wherein said carrier comprises a surfactant, a lubricant, and methyl paraben.

20. The composition of claim 19, wherein said carrier comprises 97.25% w/w phosphatidylcholine component, 1.00% w/w surfactant, 1.00% w/w lubricant, and 0.75% w/w methyl paraben.

21. The composition of claim 15, wherein said carrier further comprises water.

22. The composition of claim 16, wherein said carrier comprises 53.25% w/w phosphatidylcholine component, 1.00% w/w surfactant, 1.00% w/w lubricant, 0.75% w/w methyl paraben and 45% w/w water.

23. The composition of claim 19, wherein said surfactant is a siloxylated polyether.

24. The composition of claim 23, wherein said wherein said siloxylated polyether is dimethyl, methyl(propylpolyethylene oxide propylene oxide, acetate) siloxane.

25. The composition of claim 23, wherein said lubricant is silicone fluid.

26. The composition of claim 25, wherein said silicone fluid contains low viscosity polydimethylsiloxane polymers.

27. A method for administering a drug comprising applying to skin composition containing:

an effective amount of said drug,

a carrier having a phosphatidylcholine component entrapping said drug, wherein said carrier stabilizes said drug at room temperature.

28. The method of claim 27, wherein said phosphatidylcholine component comprises polyenylphosphatidylcholine and at least one polyglycol.

29. The method of claim 28, wherein said polyglycol is polyglycol E200 and polyglycol E400.

30. The method of claim 29, wherein said phosphatidylcholine component comprises 45% w/w polyenylphosphatidylcholine, 50% w/w polyglycol E200, and 5% w/w polyglycol E400.

31. The method of claim 27, wherein said carrier comprises a surfactant, a lubricant, and methyl paraben.

32. The method of claim 31, wherein said carrier comprises 97.25% w/w phosphatidylcholine component, 1.00% w/w surfactant, 1.00% w/w lubricant, and 0.75% methyl paraben.

33. The method of claim 31, wherein said carrier further comprises water.

34. The method of claim 33, wherein said carrier comprises 53.25% w/w phosphatidylcholine component, 1.00% w/w surfactant, 1.00% lubricant, 0.75% w/w methyl paraben and 45% w/w water.

35. The method of claim 31, wherein said surfactant is a siloxylated polyether.

36. The method of claim 35, wherein said siloxylated polyether is dimethyl, methyl(propylpolyethylene oxide propylene oxide, acetate) siloxane.

37. The method of claim 31, wherein said lubricant is silicone fluid.

38. The method of claim 37, wherein said silicone fluid contains low viscosity polydimethylsiloxane polymers.

39. The method of claim 27, wherein said drug is selected from the group consisting of oxytocin, vasopressin, insulin, somatotropin, calcitonin, chorionic gonadotropin, menotropins, follitropins, somatostatins, progestins, and combinations of any of these.